Anzeige
Mehr »
Donnerstag, 02.10.2025 - Börsentäglich über 12.000 News
Globaler Gamechanger: CiTech expandiert in Europa - neue Chancen für Investoren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PYWB | ISIN: US09203E1055 | Ticker-Symbol:
NASDAQ
01.10.25 | 21:58
3,710 US-Dollar
-2,11 % -0,080
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BLACK DIAMOND THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
BLACK DIAMOND THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur BLACK DIAMOND THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
BLACK DIAMOND THERAPEUTICS Aktie jetzt für 0€ handeln
DiFreedom Capital Markets startet Coverage für Black Diamond Therapeutics mit "Buy"-Rating3
DiBlack Diamond Therapeutics stock initiated with Buy rating at Freedom Capital1
25.09.Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?1
23.09.BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?2
12.09.Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?2
05.09.BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?2
04.09.Black Diamond Therapeutics stock initiated with Buy rating at Guggenheim2
11.08.H.C. Wainwright lowers Black Diamond Therapeutics stock price target on delayed launch43
07.08.Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update224Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025Exploring partnership...
► Artikel lesen
07.08.Black Diamond Therapeutics, Inc. - 10-Q, Quarterly Report1
07.08.Black Diamond Therapeutics, Inc. - 8-K, Current Report2
12.06.Black Diamond Therapeutics, Inc. - 8-K, Current Report2
12.05.Black Diamond Therapeutics GAAP EPS of $0.98 beats by $0.96, revenue of $70M3
12.05.Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update347Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma...
► Artikel lesen
12.05.Black Diamond Therapeutics, Inc. - 8-K, Current Report1
19.03.Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics1.198BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over...
► Artikel lesen
19.03.Black Diamond Therapeutics, Inc: Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy286The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with...
► Artikel lesen
06.03.Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update808Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored "window of opportunity" trial into newly diagnosed...
► Artikel lesen
05.11.24Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update240Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024 Presented...
► Artikel lesen
07.10.24Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway253Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize BDTX-4933 and seek potential partners Anticipated cost savings expected to extend cash runway...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1